Foshan Bliss Biotechnology Co., Ltd. – Trademark Portfolio

Entity Type: 16

Foshan Bliss Biotechnology Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include HALPTIFY. The owner is based in Sanshui Dist, Foshan.

Room 905, Block 15, Jiuyue Huayuan

No. 2, Qili Avenue North, Leping Town

Sanshui Dist, Foshan 528137 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

HALPTIFY
HALPTIFY
Registered 2025

Trademark Classifications

Foshan Bliss Biotechnology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

3
Cosmetics & Cleaning (1 filing)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

Frequently Asked Questions

How many trademarks does Foshan Bliss Biotechnology Co., Ltd. have?

Foshan Bliss Biotechnology Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Foshan Bliss Biotechnology Co., Ltd. file in?

Foshan Bliss Biotechnology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 3 (Cosmetics & Cleaning). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.

What are Foshan Bliss Biotechnology Co., Ltd.'s most well-known trademarks?

Foshan Bliss Biotechnology Co., Ltd.'s registered trademark portfolio includes well-known marks such as HALPTIFY. These are among 1 currently registered trademark in the portfolio.

What is Foshan Bliss Biotechnology Co., Ltd.'s trademark registration success rate?

Foshan Bliss Biotechnology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.